pyrazines has been researched along with celecoxib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Mack, GS | 1 |
| Chaudhary, U; Dunder, S; Green, M; Hayslip, J; Kraft, A; Meyer, M; Montero, AJ; Salzer, S; Sherman, C | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Kardosh, A; Louie, SG; Petasis, NA; Pyrko, P; Schönthal, AH; Uddin, J | 1 |
| Chen, ST; Gaffney, KJ; Louie, SG; Petasis, NA; Schönthal, AH; Thomas, S | 1 |
| Hur, DY; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Lee, JI; Lee, WJ; Park, GB; Wu, TC | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
1 trial(s) available for pyrazines and celecoxib
| Article | Year |
|---|---|
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Pyrazoles; Sulfonamides | 2007 |
6 other study(ies) available for pyrazines and celecoxib
| Article | Year |
|---|---|
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biotechnology; Boronic Acids; Bortezomib; Celecoxib; Cyanides; Drug Industry; Etanercept; Guanidines; Humans; Immunoglobulin G; Interleukin 1 Receptor Antagonist Protein; NF-kappa B; Patents as Topic; Protein C; Pyrazines; Pyrazoles; Raloxifene Hydrochloride; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Rituximab; Sialoglycoproteins; Sulfonamides; United States | 2006 |
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Glioblastoma; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Pyrazines; Pyrazoles; Sulfonamides; Transfection; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.
Topics: Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Humans; Lymphoma; Pyrazines; Pyrazoles; Stress, Physiological; Sulfonamides | 2010 |
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Female; G1 Phase Cell Cycle Checkpoints; Imidazoles; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Pyrazines; Pyrazoles; Pyridines; Repressor Proteins; STAT3 Transcription Factor; Sulfonamides; Transcription Factor CHOP; Uterine Cervical Neoplasms | 2014 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |